PGRN-RIKEN Collaborative StudiesThe Global Alliance for Pharmacogenomics continues to add new projects since 2008. These collaborations between scientists in the U.S. and Japan examine how genes influence individual responses to medicines. The projects focus on a wide range of drugs, including those used to treat asthma, cancer, diabetes, depression, HIV/AIDS, rheumatology, and cardiovascular disorders. The long-term goal of the effort is to help doctors to tailor treatments based on the genetic makeup of each patient. The following are the study areas that were funded through this mechanism.
Acknowledgement: Please make sure to acknowledge the PGRN-RIKEN collaboration in your publication, by including the following statement: "This publication was made possible by the Pharmacogenomics Research Network-RIKEN Global Alliance (PGRN-RIKEN), which is supported by the RIKEN Center for Integrative Medical Science and the NIH Pharmacogenomics Research Network (GM115370)." |
Cancer |
(1) Pharmacogenomics of Aromatase Inhibitors (approximate number of samples: 830)J. Ingle, R. Weinshilboum, M. Kubo
(2) Gemcitabine and Bevacizumab for Pancreatic Cancer (approximate number of samples: 352) F. Innocenti, N. Cox, K. Owzar, H. Kindler, K. Giacomini, H. McLeod, M. Ratain, Y. Nakamura (3) Aromatase Inhibitors for Breast Cancer w/ MA-27 (approximate number of samples: 1688) J. Ingle, R. Weinshilboum, D. Flockhart, V. Stearns, T. Mushiroda (4) Cyclophosphamide and Doxorubicin/Paclitaxel for Breast Cancer (approximate number of samples: 1984) D. Kroetz, E. Jorgenson, K. Owzar, J. Witte, L. Shulman, H. McLeod, M. Ratain, H. Zembutsu (5) Docetaxel/Prednisone/Bevacizumab Addition to Prostate Cancer Therapy (approximate number of samples: 835) H. McLeod, M. Ratain, D. Kroetz, Kelly, K. Ozwar, N. Cox, Motsinger-Rief, H. Zembutsu (6) Tamoxifen/Raloxifene Adjuvant to Treat Breast Cancer NSABP (approximate number of samples: 1848) J. Ingle, Wickerham, D. Schaid, Costantino, Vogel, Paik, P. Goetz, D. Flockhart, Wolmark, R. Weinshilboum, H. Zembutsu (7) Celecoxib Effectiveness for Colorectal Cancer (approximate number of samples: 1660) M. Bertagnolli, S. Weiss, J. Su, M. Ratain, K. Owzar, K. Matsuda (8) Busulfan-Based Chemotherapy and Acute Myelogenous Leukemia (approximate number of samples: 328) C. Andreadis, K. Giacomini, S. W. Yee, J. Witte, L. Johnston, S. Baker, M. Relling, M. Baer, D. Kroetz, K. Matsuda (9) Aromatase Inhibitors and Bone Fractures (approximate number of samples: 1848) P. Goss, D. Schaid, J.-A. Chapman, S. Khosla, L. Shepherd, M. Ellis, V. Stearns, D. Flockhart, R. Weinshilboum, J. Ingle, H. Zembutsu (10) Colorectal Cancer Pharmacogenetics (approximate number of samples: 1000) H. McLeod, K. Owzar, M. Ratain, A. Venook, P.N. Friedman, M. Bertagnolli, H. Zembutsu. (11) Patients Experiencing Breast Events While Receiving Aromatase Inhibitors for Early Breast Cancer on NCIC CTG Trial MA.27 (approximately 270 samples with additional samples already genotyped in previous round). M. Ellis, J. Ingle, P. Goss, D. Schaid, J-A. Chapman, L. Shepherd, R. Weinshilboum, M. Kubo. (12) Addition of bevacizumab to standard carboplatin-paclitaxel chemotherapy in patients with advanced ovarian cancer. (approximate number of samples: 492) G. Liu, H. Mackay, W. Xu, A. Oza, K. Matsuda. (13) Genome-Wide Association Study in Patients Receiving Neoadjuvant Chemotherapy with or without Bevacizumab on NSABP B40 (approximate number of samples: 1114) J. Ingle, Y. Furukawa (14) Colorectal Cancer Pharmacogenetics (Phase II) (approximate number of samples: 633) F. Innocentti, Y. Furukawa, K. Owzar (15) Pharmacogenetic Analysis of Cetuximab (CO.20 Trial) (approximate number of samples: 664) G. Liu, T. Mushiroda, K. Matsuda (16) Sequencing Across GWAS Signals Relating to Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors for Adjuvant Therapy of Early Breast Cancer (MA.27) (approximate number of samples: 912) J. Ingle, T. Momozawa, T. Mushiroda (17) Pharmacogenetic Predictors of Peripheral Neuropathy Associated with Microtubule Targeting Drugs (approximate number of samples: 651) D. Kroetz, T. Mushiroda (18) Polygenic modeling of chemotherapy-induced peripheral neurotoxicity and ototoxicity (approximate number of samples: 1244) E. Dolan, T. Mushiroda (19) Sequencing Across GWAS Signals Relating to Breast Events in Women Receiving Aromatase Inhibitors for Adjuvant Therapy of Early Breast Cancer (MA.27) (approximate number of samples: 1016) J. Ingle, Y. Momozawa (20) Replication GWAS of Cisplatin-Induced Peripheral Neuropathy and Ototoxicity (approximate number of samples: 492) E. Dolan, T. Mushiroda (21) The relationship of the pharmacogenetics of enzalutamide to its pharmacokinetic disposition /metabolism and clinical pharmacodynamics in advanced prostate cancer patients enrolled in the Alliance A031201 study (approximate number of samples: 1075) L. Lewis, T. Mushiroda, K. Matsuda, M. J. Morris, J. H. Beumer, J. Gobbaru, K. Owzar, S. Halabi, M. Sharma, M. J. Ratain, H. McLeod |
Cardiovascular Disease |
(1) International Warfarin PGx Consortium (IWPC) (approximate number of samples: 1000)
J.A. Johnson, D. Roden, M. Caldwell for the International Warfarin Pharmagenomics Consortium, IWPC, T. Mushiroda (2) Drug-induced Long QT Syndrome Genetic Prediction (approximate number of samples: 1000) D. Roden, M. Province, M. Ritchie, A.L. George, T. Tanaka (3) ACE Inhibitors and Andiogedema (approximate number of samples: 818) N. Brown, D. Roden, S. Williams, C. Ingram, R. Krauss, C. McCarty, M. Kubo (4) AV Nodal Blocking Agents for Atrial Fibrillation (approximate number of samples: 2000) D. Darbar, D. Roden, M. Province, M. Ritchie, H. Okafor, P. Ellinor, S. Kabb, H. Watanabe, T. Tanaka (5) Adverse Cardiovascular Outcomes and New-onset Diabetes after Antihypertensive Therapy (approximately 1690) J.A. Johnson, R. Cooper-DeHoff, Y. Gong, C. Pepine, S. Padmanabhan, A.F. Dominiczak, M. Caulfield, T. Tanaka (6) International Clopidogrel Pharmacogenomics Consortium (ICPC) Genome-wide Association Study (approximate number of samples: 3000) A. Shuldiner, T. Mushiroda (7) Genetic Determinants of Clinical Cardiovascular Events in Patients Receiving Statins (approximate number of samples: 6066) R. Krauss, D. Roden, J. Denny, W-Q. Wei, C.M. Stein, C. Ingram, Q. Feng, X.Li, J.I. Rotter, M. Kubo (8) Genetic Determinants of Heparin-Induced Thrombocytopenia (approximate number of samples: 5285) D. Roden, J. Karnes, T. Mushiroda (9) Genetic Biomarkers of Venous Thromboembolism in Large African American and Caucasian Cancer Cohorts (approximate number of samples: 629 African Americans) M. Perera, K. Ito, J. R. Brewer, M. J. Ratain, P. N. Friedman, K. Owzar, H. McLeod, L. Lewis |
Endocrinology |
(1) Genetic Determinants of Glycemic Response to Metformin in Type 2 Diabetes (approximate number of samples: 500)
K. Giacomini, S.W. Yee, S. Maeda (2) Genomewide Association Study of Metformin Glycemic Response and Gastro-Intestinal Side Effects in African Americans (approximate number of samples: 1000) K. Giacomini, S.W. Yee, S. Maeda (3) Genomewide Meta-Analysis of Metformin Glycemic Response in Multi-Ethnic Cohorts (approximate number of samples: 4500) K. Giacomini, Y. Kamatani |
HIV/AIDS |
(1) Antiretrovirals for HIV Infection in Uganda (approximate number of samples: 500)
D. Kroetz, D. Bangsberg, J. Martin, P. Hunt, E. Jorgenson, J. Witte, H. McLeod, M. Wagner, T. Mushiroda |
Inflammatory Disease |
(1) Pharmacogenomics of response to Anti-TNF-alfa biologic agent in Inflammatory Bowel Disease (IBD) (approximate number of samples: 1043)
M. Perera, Y. Momozawa |
Neuropsychiatric Disease |
(1) Citalopram and Escitalopram for Depression (approximate number of samples: 500)
D. Mrazek, C. Schaefer, D. Schaid, K. Giacomini, and R. Weinshilboum, T. Mushiroda (2) SSRIs and Depression-European Consortium (approximate number of samples: 2000) D. Mrazek, J. Kirchheiner, T. Klein, D. Schaid, R. Altman, K. Giacomini, R. Weinshilboum, T. Mushiroda (3) Deep Sequencing Across Nicotine Metabolism Genes Associated with Smoking Cessation Outcomes (approximate number of samples: 1682) R. Tyndale, T. Mushiroda, K. Fukunaga |
Pulmonary Disease |
(1) Inhaled beta-Agonists for Asthma (approximate number of samples: 1121)
S. Weiss, A. Litonjua, K. Tantisira, M. Ritchi, M. Tamari (2) Corticosteroid and Inhaled Short-Acting Beta Agonists and Asthma (approximate number of samples: 1041) S. Weiss, K. Tantisira, A. Litonjua, J. Lasky-Su, M. Tamari (3) Genome-Wide Association Study of 5-Lipoxygenase Inhibition in Asthma (approximate number of samples: 300) K. Tantisira, M. Tamari (4) Pharmacogenetics of Prostacyclin Dosing in Pulmonary Arterial Hypertension (approximate number of samples: 1198) M. Gomberg-Maitland, M. Maitland, M. Tamari (5) Development of a Pharmacogenetic Test that Predicts Response to Inhaled Corticosteroids in Asthmatics in Large Real-life Populations (approximate number of samples: 1742) A. Wu, S. Weiss, M. Tamari (6) Deep sequencing of genes associated with glucocorticoid response in Asthma (approximate number of samples: 723) K. Tantisira, S. Weiss, Y. Momozawa, M. Tamari |
Rheumatology |
(1) Pharmacogenomics of Methotrexate Response in Patients with Rheumatoid Arthritis (approximate number of samples: 1600)
T. Bongartz, Y. Kochi (2) Transethnic Genome-wide Analysis to Identify Genetic Determinants of Allopurinol Response (approximate number of samples: 1920) K. Giacomini, Y. Kamatani |